Department of Defense Neurofibromatosis New Investigator Award for Promising Researchers

Opportunity ID: 45129

General Information

Document Type: Grants Notice
Funding Opportunity Number: W81XWH-09-NFRP-NIA
Funding Opportunity Title: DOD Neurofibromatosis New Investigator Award
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Grant
Category of Funding Activity: Science and Technology and other Research and Development
Category Explanation:
Expected Number of Awards: 2
Assistance Listings: 12.420 — Military Medical Research and Development
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Feb 02, 2009
Last Updated Date:
Original Closing Date for Applications: Apr 14, 2009
Current Closing Date for Applications: Apr 14, 2009
Archive Date: May 14, 2009
Estimated Total Program Funding: $1,200,000
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility”
Additional Information on Eligibility:

Additional Information

Agency Name: Dept. of the Army — USAMRAA
Description: The NFRP New Investigator Award (NIA) mechanism was first offered in FY99. Since that time, 266 NIA applications have been received and 36 have been recommended for funding.
The intent of the NFRP NIA is to support the career transition and/or continued development of promising independent investigators in the field of neurofibromatosis research. Experience in NF research is allowed, but not required. However, Principal Investigators (PIs) with a limited background in NF research are strongly encouraged to have a collaborator who is experienced in the NF field. To be eligible for this award, PIs must meet the eligibility requirements specified below in Section I.C. NIA proposals must include preliminary data originating from the PI, research team, or collaborator that is relevant to NF and the proposed project.
Areas of Encouragement (Revised for FY09): The FY09 NFRP encourages research proposals that specifically address the critical needs of the NF community in the following areas:
• Complications of NF with high mortality such as neoplasms and cerebrovascular abnormalities;
DOD Neurofibromatosis New Investigator Award 3
• Complications of NF with high morbidity such as skeletal maladies, learning deficits, hormone-associated effects, and pain;
• Refinement and standardization of imaging techniques, molecular and cellular markers, and quality of life metrics for use in future clinical trials; and
• Translational research such as the development or preclinical testing of therapeutic agents for the treatment of NF.
Clinical trials are not allowed under this mechanism. PIs wishing to apply for funding for a clinical trial should utilize the Clinical Trial Award mechanism. See the Program Announcement for the full Funding Opportunity Description.
Link to Additional Information:
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

PA HELP: 301-619-7079; cdmrp.pa@amedd.army.mil

eReceipt HELP: 301-682-5507; help@cdmrp.org

Email:cdmrp.pa@amedd.army.mil

Version History

Version Modification Description Updated Date

Folder 45129 Full Announcement-1 -> biosketch.pdf

Folder 45129 Full Announcement-1 -> NF09 NIA_PA.pdf

Folder 45129 Full Announcement-1 -> Budget Form Reader.pdf

Folder 45129 Full Announcement-1 -> NF09 NIA Statement of Eligibility fillable.pdf

Packages

Agency Contact Information: PA HELP: 301-619-7079; cdmrp.pa@amedd.army.mil
eReceipt HELP: 301-682-5507; help@cdmrp.org

Email: cdmrp.pa@amedd.army.mil

Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
12.420 PKG00010304 Feb 02, 2009 Apr 14, 2009 View

Package 1

Mandatory forms

45129 RR_SF424-1.1.pdf

45129 RR_PerformanceSite-1.1.pdf

45129 RR_KeyPersonExpanded-1.1.pdf


Comments

Leave a Reply

Your email address will not be published. Required fields are marked *